How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

15,970 results for

HIV Course

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

161. Guidelines on HIV self-testing and partner notification

) but is not well established in the general population. This type of epidemic suggests that there are active networks of people with high risk behaviours within the subpopulation. The future course of the epidemic is determined by the nature of the links between subpopulations with a high HIV prevalence and the general population. Numerical proxy: HIV prevalence is consistently over 5% in at least one defined subpopulation but is below 1% in pregnant women attending antenatal clinics. Confirm: to issue (...) Guidelines on HIV self-testing and partner notification SUPPLEMENT GUIDELINES ON HIV TESTING SERVICES DECEMBER 2016 HIV SELF-TESTING AND PARTNER NOTIFICATION SUPPLEMENT TO CONSOLIDATED GUIDELINES ON HIV TESTING SERVICES#Test4HIV SUPPLEMENT GUIDELINES ON DECEMBER 2016 HIV SELF-TESTING AND PARTNER NOTIFICATION SUPPLEMENT TO CONSOLIDATED GUIDELINES ON HIV TESTING SERVICESWHO Library Cataloguing-in-Publication Data Guidelines on HIV self-testing and partner notification: supplement to consolidated

2016 World Health Organisation HIV Guidelines

162. Consolidated guidelines on HIV prevention, diagnosis, treatment and care for key populations

Consolidated guidelines on HIV prevention, diagnosis, treatment and care for key populations GUIDELINES CONSOLIDATED GUIDELINES ON HIV PREVENTION, DIAGNOSIS, TREATMENT AND CARE FOR KEY POPULATIONS KEY POPULATIONS ISBN 978 92 4 151112 4 For more information, contact: World Health Organization Department of HIV/AIDS 20, avenue Appia 1211 Geneva 27 Switzerland E-mail: hiv-aids@who.int http://www.who.int/hiv/pub/guidelines/ keypopulations/ 2016 UPDATE CONSOLIDATED GUIDELINES ON HIV PREVENTION (...) , DIAGNOSIS, TREATMENT AND CARE FOR KEY POPULATIONSCONSOLIDATED GUIDELINES ON HIV PREVENTION, DIAGNOSIS, TREATMENT AND CARE FOR KEY POPULATIONS 2016 UPDATEWHO Library Cataloguing-in-Publication Data : Consolidated guidelines on HIV prevention, diagnosis, treatment and care for key populations – 2016 update. 1.HIV Infections - prevention and control. 2.HIV Infections - therapy. 3.HIV Infections – diagnosis. 4.Risk Factors. 5.Vulnerable Populations. 6.Guideline. I.World Health Organization. ISBN 978 92 4

2016 World Health Organisation HIV Guidelines

163. Guidelines for HIV mortality measurement

idea of the leading causes of death. This is done to obtain the overall picture and to assess the importance of specific diseases. In 2012, an estimated 1.6 million (range 1.4 to 1.9 million) people died from HIV-related causes, including 1.2 million (range 1.1 to 1.3 million) in sub-Saharan Africa (4). These estimates are based on country data that have been analysed in statistical models, using standard methods developed to estimate the course of the HIV/AIDS epidemic. The main input is HIV (...) Guidelines for HIV mortality measurement For more information, contact: World Health Organization Department of HIV/AIDS Avenue Appia 20 1211 Geneva 27 Switzerland E-mail: hiv-aids@who.int www.who.int/hiv Guidelines for HIV mortality measurement UNAIDS/WHO Working Group on Global HIV/AIDS and STI Surveillance ISBN 978 92 4 150557 4WHO Library Cataloguing-in-Publication Data Guidelines for HIV mortality measurement. 1.HIV infections – mortality. 2.Death certificates. 3.Registries 4.National

2015 World Health Organisation HIV Guidelines

164. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection

Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection For more information, contact: World Health Organization Department of HIV/AIDS 20, avenue Appia 1211 Geneva 27 Switzerland E-mail: hiv-aids@who.int http://www.who.int/hiv ISBN 978 92 4 154968 4 GUIDELINES CONSOLIDATED GUIDELINES ON THE USE OF ANTIRETROVIRAL DRUGS FOR TREATING AND PREVENTING HIV INFECTION 2016 RECOMMENDATIONS FOR A PUBLIC HEALTH APPROACH SECOND EDITION CONSOLIDATED GUIDELINES (...) ON THE USE OF ANTIRETROVIRAL DRUGS FOR TREATING AND PREVENTING HIV INFECTIONCONSOLIDATED GUIDELINES ON THE USE OF ANTIRETROVIRAL DRUGS FOR TREATING AND PREVENTING HIV INFECTION 2016 RECOMMENDATIONS FOR A PUBLIC HEALTH APPROACH SECOND EDITIONWHO Library Cataloguing-in-Publication Data Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach – 2nd ed. 1.HIV Infections – drug therapy. 2.HIV Infections – prevention

2016 World Health Organisation HIV Guidelines

165. Factors associated with tuberculosis treatment delay in patients co-infected with HIV in a high prevalence area in Brazil. (PubMed)

a prospective cohort study of patients diagnosed with TB at the National Institute of Infectious Disease, at the Oswaldo Cruz Foundation, Rio de Janeiro, Brazil we conducted a survival analysis to identify factors associated with patient and health care treatment delay. In our analysis we included patients who were co-infected with TB and HIV (n = 201). Patients were followed during the course of their TB treatment and information regarding duration of symptoms, sociodemographics and clinical (...) Factors associated with tuberculosis treatment delay in patients co-infected with HIV in a high prevalence area in Brazil. Worldwide, about 11% of Tuberculosis (TB) cases occur in people living with HIV (PLHIV) and it is the leading cause of death in this population. An important step towards reducing the incidence and mortality of TB in PLHIV is to reduce the time from onset of symptoms to treatment. Factors related to TB treatment delay therefore need to be understood.Using data from

Full Text available with Trip Pro

2018 PLoS ONE

166. Immunological and virological benefits resulted from short-course treatment during primary HIV infection: a meta-analysis. (PubMed)

Immunological and virological benefits resulted from short-course treatment during primary HIV infection: a meta-analysis. To assess the potential immunological and virological effects that result from short-course antiretroviral treatment during primary HIV infection (PHI). And to investigate whether treatment initiation time, treatment duration and follow-up time after treatment interruption would affect these post-treatment immunovirological outcomes.We systematically searched PubMed (...) . Extending treatment duration beyond 12 months did not increase efficacy.Short-course treatment during PHI was associated with immunological and virological benefits which last for at least one year after treatment interruption. The conclusions from our study would help the decision-making in the clinical management of PHI.

Full Text available with Trip Pro

2013 PloS one

167. Assessment of VAC-3S Therapeutic Properties When Combined With Standard ART in the Course of HIV-1 Infection

Assessment of VAC-3S Therapeutic Properties When Combined With Standard ART in the Course of HIV-1 Infection Assessment of VAC-3S Therapeutic Properties When Combined With Standard ART in the Course of HIV-1 Infection - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (...) (100). Please remove one or more studies before adding more. Assessment of VAC-3S Therapeutic Properties When Combined With Standard ART in the Course of HIV-1 Infection The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02041247 Recruitment Status : Unknown Verified June 2016 by InnaVirVax

2013 Clinical Trials

168. The Impact of Helicobacter Pylori Infection on Immune Regulation and Clinical Course in HIV Patients in Ghana

The Impact of Helicobacter Pylori Infection on Immune Regulation and Clinical Course in HIV Patients in Ghana The Impact of Helicobacter Pylori Infection on Immune Regulation and Clinical Course in HIV Patients in Ghana - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (...) (100). Please remove one or more studies before adding more. The Impact of Helicobacter Pylori Infection on Immune Regulation and Clinical Course in HIV Patients in Ghana (HHECO) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01897909 Recruitment Status : Active, not recruiting First Posted : July

2013 Clinical Trials

169. Short communication: effect of short-course antenatal zidovudine and single-dose nevirapine on the BED capture enzyme immunoassay levels in HIV type 1 subtype C infection. (PubMed)

Short communication: effect of short-course antenatal zidovudine and single-dose nevirapine on the BED capture enzyme immunoassay levels in HIV type 1 subtype C infection. Cross-sectional prevalence studies based on immunoassays that discriminate between recent and long-term infections, such as the BED assay, have been widely used to estimate HIV incidence. However, individuals receiving highly active antiretroviral therapy tend to have lower BED levels and are associated with a higher risk (...) gestation through delivery and were randomized to receive either sdNVP or placebo during labor. Among 159 subjects, the OD-n levels decreased from baseline to delivery in 93 subjects (p=0.039), suggesting that short-course ZDV may decrease OD-n levels. sdNVP at delivery did not affect longitudinal BED OD-n levels postdelivery. However, sdNVP appeared to modify the association between CD4 count at delivery and OD-n levels postdelivery. When estimating HIV incidence with the BED assay, special care may

Full Text available with Trip Pro

2013 AIDS research and human retroviruses Controlled trial quality: uncertain

170. Virological response to short-course maraviroc monotherapy does not predict viral tropism in HIV-1-infected treatment-naive patients. (PubMed)

Virological response to short-course maraviroc monotherapy does not predict viral tropism in HIV-1-infected treatment-naive patients. We aimed to evaluate whether virological response to a short course of maraviroc monotherapy could predict HIV-1 tropism.A clinical trial was performed in HIV-1 treatment-naive patients infected with R5- or non-R5-tropic virus determined using the Trofile(®) assay, with >1000 HIV-1 RNA copies/mL. Maraviroc was administered for 10 days. Viral load was measured (...) at baseline and days 4, 7, 10 and 28. The main outcome measurement was the decline in HIV-1 RNA at day 10. The trial was registered in the ClinicalTrials.gov database (NCT01060618; TROPISMVC).Forty patients [30 R5 and 10 dual/mixed (D/M)] were recruited. There was a significant decrease in HIV-1 RNA after 10 days of maraviroc treatment in patients with R5-tropic virus (median 1.52 log10 RNA copies/mL; 95% CI 1.23-1.63; P < 0.0001), but also in patients with D/M-tropic virus (median 1.62 log(10) RNA copies

Full Text available with Trip Pro

2014 Journal of Antimicrobial Chemotherapy

171. Drift of the HIV-1 Envelope Glycoprotein gp120 toward Increased Neutralization Resistance over the Course of the Epidemic: a Comprehensive Study Using the Most Potent and Broadly Neutralizing Monoclonal Antibodies (PubMed)

Drift of the HIV-1 Envelope Glycoprotein gp120 toward Increased Neutralization Resistance over the Course of the Epidemic: a Comprehensive Study Using the Most Potent and Broadly Neutralizing Monoclonal Antibodies Extending our previous analyses to the most recently described monoclonal broadly neutralizing antibodies (bNAbs), we confirmed a drift of HIV-1 clade B variants over 2 decades toward higher resistance to bNAbs targeting almost all the identified gp120-neutralizing epitopes

Full Text available with Trip Pro

2014 Journal of virology

172. Guidelines for the Care of Pregnant Women Living With HIV and Interventions to Reduce Perinatal Transmission: Executive Summary

Guidelines for the Care of Pregnant Women Living With HIV and Interventions to Reduce Perinatal Transmission: Executive Summary Guidelines for the Care of Pregnant Women Living With HIV and Interventions to Reduce Perinatal Transmission: Executive Summary - Journal of Obstetrics and Gynaecology Canada Email/Username: Password: Remember me Search Terms Search within Search Volume 36, Issue 8, Pages 721–734 Guidelines for the Care of Pregnant Women Living With HIV and Interventions to Reduce (...) the full text on ScienceDirect. Abstract Objective This guideline reviews the evidence relating to the care of pregnant women living with HIV and the prevention of perinatal HIV transmission. Prenatal care of pregnancies complicated by HIV infection should include monitoring by a multidisciplinary team with experts in this area. Outcomes Outcomes evaluated include the impact of HIV on pregnancy outcome and the efficacy and safety of antiretroviral therapy and other measures to decrease the risk

2014 Society of Obstetricians and Gynaecologists of Canada

173. Guidelines for conducting HIV surveillance among pregnant women attending antenatal clinics based on routine programme data

. The guidance is based on the input of surveillance experts and surveillance programmes, and lessons learnt from the field. Countries may adopt or adapt this guidance as appropriate.9 Guidelines for conducting HIV surveillance based on routine programme data 1.2 HIV surveillance among pregnant women in the context of second-generation surveillance: know your epidemic Countries require information on HIV prevalence to monitor the course of their HIV epidemics and to allocate resources, and plan and evaluate (...) Guidelines for conducting HIV surveillance among pregnant women attending antenatal clinics based on routine programme data GUIDELINES CONDUCTING HIV SURVEILLANCE BASED ON ROUTINE PROGRAMME DATA AMONG PREGNANT WOMEN ATTENDING ANTENATAL CLINICS UNAIDS/WHO working group on global HIV/AIDS and STI surveillance AUGUST 2015 HIV STRATEGIC INFORMATION FOR IMPACTWHO Library Cataloguing-in-Publication Data: Guidelines for conducting HIV surveillance among pregnant women attending antenatal clinics based

2015 World Health Organisation HIV Guidelines

174. Consolidated guidelines on HIV testing services

that there are active networks of people with high risk behaviours within the subpopulation. The future course of the epidemic is determined by the nature of the links between subpopulations with a high HIV prevalence and the general population. Numerical proxy: HIV prevalence is consistently over 5% in at least one defined subpopulation but is below 1% in pregnant women attending antenatal clinics. Confirmed: to issue an HIV status, initially reactive test results need to be confirmed according to the national (...) Consolidated guidelines on HIV testing services GUIDELINES CONSOLIDATED GUIDELINES ON HIV TESTING SERVICES ISBN 978 92 4 150892 6 For more information, contact: World Health Organization Department of HIV 20, avenue Appia 1211 Geneva 27 Switzerland E-mail: hiv-aids@who.int http://www.who.int/hiv/pub/guidelines/ keypopulations/ JULY 2015 HIV TESTING SERVICES 5Cs: CONSENT, CONFIDENTIALITY, COUNSELLING, CORRECT RESULTS AND CONNECTION CONSOLIDATED GUIDELINES ON HIV TESTING SERVICES, 5Cs: CONSENT

2015 World Health Organisation HIV Guidelines

175. Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV

for HIV and then assessed for treatment eligibility. Those considered eligible for treatment should be offered combination lifelong antiretroviral therapy for their own health, while those who were not eligible should receive short courses of antiretroviral prophylaxis for PMTCT. Although eligibility criteria have changed and the preferred regimens for ART and for PMTCT prophylaxis have evolved, this distinction between treatment and prophylaxis became a fixture of PMTCT programmes. In 2013 (...) Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV GUIDELINE ON WHEN TO START ANTIRETROVIRAL THERAPY AND ON PRE-EXPOSURE PROPHYLAXIS FOR HIV SEPTEMBER 2015 GUIDELINESThis early-release guideline will form part of the updated WHO consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection due to be published in 2016.GUIDELINE ON WHEN TO START ANTIRETROVIRAL THERAPY AND ON PRE-EXPOSURE PROPHYLAXIS FOR HIV SEPTEMBER

2015 World Health Organisation HIV Guidelines

176. Consolidated guidelines on HIV prevention, diagnosis, treatment and care for key populations

Consolidated guidelines on HIV prevention, diagnosis, treatment and care for key populations GUIDELINES CONSOLIDATED GUIDELINES ON HIV PREVENTION, DIAGNOSIS, TREATMENT AND CARE FOR KEY POPULATIONS KEY POPULATIONS ISBN 978 92 4 150743 1 For more information, contact: World Health Organization Department of HIV/AIDS 20, avenue Appia 1211 Geneva 27 Switzerland E-mail: hiv-aids@who.int http://www.who.int/hiv/pub/guidelines/ keypopulations/ JULY 2014 CONSOLIDATED GUIDELINES ON HIV PREVENTION (...) , DIAGNOSIS, TREATMENT AND CARE FOR KEY POPULATIONSCONSOLIDATED GUIDELINES ON HIV PREVENTION, DIAGNOSIS, TREATMENT AND CARE FOR KEY POPULATIONS JULY 2014WHO Library Cataloguing-in-Publication Data : Consolidated guidelines on HIV prevention, diagnosis, treatment and care for key populations. 1.HIV Infections - prevention and control. 2.HIV Infections - therapy. 3.HIV Infections – diagnosis. 4.Risk Factors. 5.Vulnerable Populations. 6.Guideline. I.World Health Organization. ISBN 978 92 4 150743 1 (NLM

2014 World Health Organisation HIV Guidelines

177. March 2014 supplement to the 2013 consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection

March 2014 supplement to the 2013 consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection MARCH 2014 SUPPLEMENT TO THE 2013 CONSOLIDATED GUIDELINES ON THE USE OF ANTIRETROVIRAL DRUGS FOR TREATING AND PREVENTING HIV INFECTION RECOMMENDATIONS FOR A PUBLIC HEALTH APPROACH SUPPLEMENTSUPPLEMENT MARCH 2014 SUPPLEMENT TO THE 2013 CONSOLIDATED GUIDELINES ON THE USE OF ANTIRETROVIRAL DRUGS FOR TREATING AND PREVENTING HIV INFECTION RECOMMENDATIONS FOR A PUBLIC (...) HEALTH APPROACH4 WHO Library Cataloguing-in-Publication Data MARCH 2014 SUPPLEMENT TO THE 2013 CONSOLIDATED GUIDELINES ON THE USE OF ANTIRETROVIRAL DRUGS FOR TREATING AND PREVENTING HIV INFECTION. Recommendations for a public health approach. I.World Health Organization. ISBN 978 92 4 150683 0 Subject headings are available from WHO institutional repository © World Health Organization 2014 All rights reserved. Publications of the World Health Organization are available on the WHO web site (www

2014 World Health Organisation HIV Guidelines

178. Intersectionality in HIV and Other Health-Related Research

-research, and faced “interlocking barriers (e.g. HIV- related stigma, heteronormative assumptions and discriminatory treatment) that reduced access to HIV care and support.” Thus, “intersectional interventions are required to reduce the marginalization of LBQT women,” and “they should operate across micro, meso and macro levels of change.” Other health-related research Warner and Brown [24] used an intersectionality approach, grounded in life course theory, to explore differences in the trajectories (...) Intersectionality in HIV and Other Health-Related Research Rapid Review #68: June 2013 Intersectionality in HIV and Other Health- Related Research Question What is the current knowledge/evidence on intersectionality in HIV and other health-related research? Key Take-Home Messages ? Human experiences cannot be reduced to singular characteristics as these characteristics interact with others to produce health outcomes. ? Using social categories, such as class, race, gender, sexual orientation

2013 Ontario HIV Treatment Network

179. HIV, viral hepatitis and STIs - a guide for primary care

antiretroviral therapy has transformed the course of the disease, extending the life expectancy of individuals with HIV by many years. ? STIs have a complex synergistic relationship with HIV. Most STIs play an enhancing role in the acquisition and transmission of HIV, while HIV may alter the natural history and response to treatment of some STIs. ? HBV is transmitted through mucous membrane contact (including unprotected sexual contact), blood-to-blood contact, mother-to-child transmission and intrafamilial (...) HIV, viral hepatitis and STIs - a guide for primary care HIV , VIRAL HEPATITIS & STIs SUPPOR TING THE HIV, VIR AL HEPATITIS AND SEXUAL HEALTH WORKFOR CE A GUIDE FOR PRIMARY CARE PROVIDERS HIV, VIRAL HEPATITIS & STIsHIV, VIRAL HEPATITIS AND STIs – A GUIDE FOR PRIMARY HEALTH CARE i HIV , VIRAL HEPATITIS & STIs SUPPOR TING THE HIV, VIRAL HEPATITIS AND SEXUAL HEALTH W ORKFOR CE A GUIDE FOR PRIMARY CAREii HIV, VIRAL HEPATITIS AND STIs – A GUIDE FOR PRIMARY HEALTH CAREHIV, VIRAL HEPATITIS AND STIs

2014 Clinical Practice Guidelines Portal

180. Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB. (PubMed)

Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB. Preventing active tuberculosis (TB) from developing in people with latent tuberculosis infection (LTBI) is important for global TB control. Isoniazid (INH) for six to nine months has 60% to 90% protective efficacy, but the treatment period is long, liver toxicity is a problem, and completion rates outside trials are only around 50%. Rifampicin (...) or rifamycin-combination treatments are shorter and may result in higher completion rates.To compare the effects of rifampicin monotherapy or rifamycin-combination therapy versus INH monotherapy for preventing active TB in HIV-negative people at risk of developing active TB.We searched the Cochrane Infectious Disease Group Specialized Register; Cochrane Central Register of Controlled Trials (CENTRAL); MEDLINE; EMBASE; LILACS; clinical trials registries; regional databases; conference proceedings

Full Text available with Trip Pro

2013 Cochrane

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>